Trial Search Results

Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy

Dystrophinopathy is a disease continuum that includes Duchenne muscular dystrophy, which develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is important for maintaining normal muscle structure and function. Loss of dystrophin causes muscle fragility that leads to weakness and loss of walking ability. A specific type of mutation, called a nonsense (premature stop codon) mutation is the cause of dystrophinopathy in approximately 10-15% of boys with the disease. Ataluren is an orally delivered, investigational drug that has the potential to overcome the effects of the nonsense mutation. The main goal of this Phase 3 study is to evaluate the effect of ataluren on walking ability. The effect of ataluren on physical function, quality of life, and activities of daily living will be evaluated. This study will also provide additional information on the long-term safety of ataluren.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

PTC Therapeutics


  • Drug: Ataluren
  • Drug: Placebo


Phase 3


Inclusion Criteria:

   - Ability to provide written informed consent (parental/guardian consent if
   applicable)/assent per local requirements.

   - Male sex.

   - Age ≥7 and ≤16 years.

   - Phenotypic evidence of dystrophinopathy based on the onset of characteristic clinical
   symptoms or signs (eg. proximal muscle weakness, waddling gait, and Gowers' maneuver)
   by 6 years of age, an elevated serum creatinine kinase level, and ongoing difficulty
   with walking.

   - Documentation of the presence of a nonsense point mutation in the dystrophin gene as
   determined by gene sequencing from a laboratory certified by the College of American
   Pathologists (CAP), the Clinical Laboratory Improvement Act/Amendment (CLIA) or an
   equivalent organization.

   - Documentation that a blood sample has been drawn for confirmation of the presence of a
   nonsense mutation in the dystrophin gene.

   - Use of systemic corticosteroids (prednisone, prednisolone, or deflazacort) for a
   minimum of 6 months immediately prior to start of study treatment, with no significant
   change in dosage or dosing regimen (not related to body weight change) for a minimum
   of 3 months immediately prior to start of study treatment and a reasonable expectation
   that dosage and dosing regimen will not change significantly for the duration of the

   - Ability to walk ≥150 meters unassisted during the screening 6-minute walk test.
   Patients need to be below the protocol-specified threshold for %-predicted 6MWD.

   - Results of the 2 Baseline 6MWD results must be determined as valid and results of the
   Day 2 Baseline 6MWD must be within 20% of the Day 1 Baseline 6MWD.

   - Baseline 6MWD (mean of valid Day 1 and Day 2 values) must be no more than a 20%
   reduction from the valid Screening 6MWD.

   - Confirmed screening laboratory values within the central laboratory ranges (hepatic,
   renal, and serum electrolyte parameters)

   - Willingness to abstain from sexual intercourse or employ an approved method of
   contraception during the period of study drug administration and 6-week follow-up

   - Willingness and ability to comply with scheduled visits, drug administration plan,
   study procedures, laboratory tests, and study restrictions.

Exclusion Criteria:

   - Treatment with systemic aminoglycoside antibiotics within 3 months prior to start of
   study treatment.

   - Initiation of systemic corticosteroids therapy within 6 months prior to start of study

   - Change in systemic corticosteroid therapy (eg, change in type of drug, dose
   modification not related to body weight change, schedule modification, interruption,
   or reinitiation) within 3 months prior to start of study treatment.

   - Any change (initiation, change in type of drug, dose modification, schedule
   modification,interruption, discontinuation, or reinitiation) in prophylaxis/treatment
   for congestive heart failure (CHF) within 3 months prior to start of study treatment.

   - Ongoing use of coumarin-based anticoagulants (eg. warfarin), phenytoin, tolbutamide,
   or paclitaxel.

   - Prior therapy with ataluren.

   - Known hypersensitivity to any of the ingredients or excipients of the study drug

   - Exposure to another investigational drug within 3 months prior to start of study

   - History of major surgical procedure within 6 weeks prior to start of study treatment.

   - Ongoing immunosuppressive therapy (other than corticosteroids).

   - Ongoing participation in any clinical trial (except for studies specifically approved
   by PTC Therapeutics).

   - Expectation of major surgical procedure (eg, scoliosis surgery) during the 12-month
   treatment period of the study.

   - Requirement for daytime ventilator assistance. Note: Evening ventilator assistance and
   use of bi-level positive airway pressure (Bi-PAP) therapy is allowed.

   - Uncontrolled clinical symptoms and signs of CHF (American College of
   Cardiology/American Heart Association Stage C or Stage D).

   - Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition,
   behavioral disorder, alcoholism, drug abuse), medical history, physical findings (eg.
   lower limb injury that may affect 6MWT performance), ECG findings, or laboratory
   abnormality that, in the investigator's opinion, could adversely affect the safety of
   the subject, makes it unlikely that the course of treatment or follow-up would be
   completed, or could impair the assessment of study results.

Ages Eligible for Study

7 Years - 16 Years

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Shirley Paulose